文献速递糖尿病

胰腺外分泌纤维化作为胰岛功能障碍与糖尿病的共同病因驱动因素:新型疾病修饰干预的机遇

The emerging role of pancreatic exocrine fibrosis as a common aetiological driver of islet dysfunction and diabetes: opportunities for novel disease-modifying interventions.
PubMed 文献 · Diabetologia · 2026-02-10

综述探讨胰腺外分泌纤维化作为3c型、2型和1型糖尿病共同病因驱动因素的作用。慢性胰腺炎、囊性纤维化和胰腺导管腺癌均高发糖尿病,三者合计可能超过自身免疫性1型糖尿病。胰管损伤与纤维化是共同特征,涉及胰管、胰腺星状细胞和巨噬细胞及TGF-β的促纤维化信号循环,并提出可逆转β细胞衰竭的旁分泌循环假说。抗纤维化药物吡非尼酮和尼达尼布已在非胰腺适应症常规使用,胰腺炎首次试验正在进行,值得在3c型糖尿病及后续2型和1型糖尿病中评估以糖尿病相关终点为主的试验。

要点

  • 慢性胰腺炎、囊性纤维化和胰腺导管腺癌均高发糖尿病,合计可能超过自身免疫性1型糖尿病。
  • 胰管损伤和纤维化是慢性胰腺炎、囊性纤维化和导管腺癌的共同特征。
  • 抗纤维化药物吡非尼酮和尼达尼布值得在3c型糖尿病及后续2型和1型糖尿病中评估。

核心结论

  • 胰腺外分泌纤维化可能是3c型、2型和1型糖尿病共同的病因驱动因素。
  • 激活的胰腺星状细胞、巨噬细胞与胰岛之间的旁分泌信号循环可能导致潜在可逆的β细胞衰竭。

研究设计与样本

  • 综述文献,探讨胰腺纤维化在3c型、2型和1型糖尿病发病中的潜在共同病因作用。

主要发现

  • 慢性胰腺炎、囊性纤维化和胰腺导管腺癌均与糖尿病高发相关,三者合计可能超过自身免疫性1型糖尿病。
  • 所有类型胰源性(3c型)糖尿病均以胰岛素分泌受损为特征,但即使外分泌腺体几乎完全破坏,仍维持显著胰岛β细胞量。
  • 慢性胰腺炎、囊性纤维化和导管腺癌中胰管损伤及相关纤维化为共同特征。
  • 2型和1型糖尿病中也可见胰管周围纤维化增加。
  • 涉及损伤胰管、胰腺星状细胞和巨噬细胞且以胰腺组织TGF-β水平升高为核心的促纤维化信号恶性循环被认为是胰腺外分泌纤维化的重要驱动因素。

关键数值与推荐

  • 吡非尼酮和尼达尼布被认为主要通过抑制TGF-β功能发挥作用,已在非胰腺适应症中常规临床使用,胰腺炎首次试验正在进行。

临床怎么用

  • 考虑在3c型糖尿病中开展评估吡非尼酮和尼达尼布且以糖尿病相关终点为主的试验。
  • 上述试验可进一步扩展至2型糖尿病,并在1型糖尿病中考虑联合方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Three diseases primarily affecting the exocrine pancreas-chronic pancreatitis, cystic fibrosis and pancreatic ductal adenocarcinoma-are all associated with a high incidence of diabetes. Together, they may account for more cases of diabetes than autoimmune type 1 diabetes. All forms of pancreatogenic (type 3c) diabetes are characterised by impaired insulin secretion but maintenance of significant islet beta cell mass, even in the presence of virtually complete destruction of the exocrine component of the gland. Pancreatic ductal injury and associated fibrosis are common features in chronic pancreatitis, cystic fibrosis and ductal adenocarcinoma. Increased peri-ductal fibrosis is also seen in type 2 and type 1 diabetes. Here, we review the literature regarding a potential common aetiological role of pancreatic fibrosis in the pathogenesis of type 3c, type 2 and type 1 diabetes. A vicious profibrotic signalling cycle involving injured ducts, pancreatic stellate cells and macrophages with increased levels of pancreatic tissue TGF-β at the core has increasingly been recognised as an essential driver of pancreatic exocrine fibrosis. We propose a second diabetogenic perpetual cycle comprising paracrine signalling between activated pancreatic stellate cells, macrophages and the islets themselves, leading to potentially reversible beta cell failure. The antifibrotic agents pirfenidone and nintedanib, thought to work primarily through suppression of TGF-β function, are used routinely in clinical practice for non-pancreatic indications, with a first trial in pancreatitis underway. Trials evaluating these licensed therapeutics that include primary diabetes-related endpoints and measures aiming to elucidate the underlying mechanisms of action merit consideration in type 3c diabetes and ultimately in type 2 diabetes and in combinatorial regimens in type 1 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Kattner N, Bashir A, Shaw JAM, et al. The emerging role of pancreatic exocrine fibrosis as a common aetiological driver of islet dysfunction and diabetes: opportunities for novel disease-modifying interventions. Diabetologia. 2026. PMID: 41665665. doi:10.1007/s00125-026-06678-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。